Division of Rheumatology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
J Intern Med. 2015 Mar;277(3):294-305. doi: 10.1111/joim.12338. Epub 2015 Jan 16.
First identified in human serum in the late 19th century as a 'complement' to antibodies in mediating bacterial lysis, the complement system emerged more than a billion years ago probably as the first humoral immune system. The contemporary complement system consists of nearly 60 proteins in three activation pathways (classical, alternative and lectin) and a terminal cytolytic pathway common to all. Modern molecular biology and genetics have not only led to further elucidation of the structure of complement system components, but have also revealed function-altering rare variants and common polymorphisms, particularly in regulators of the alternative pathway, that predispose to human disease by creating 'hyperinflammatory complement phenotypes'. To treat these 'complementopathies', a monoclonal antibody against the initiator of the membrane attack complex, C5, has received approval for use. Additional therapeutic reagents are on the horizon.
早在 19 世纪末期,人们就在人血清中首次发现一种作为抗体介导细菌裂解的“补体”,补体系统在超过十亿年前可能就作为第一个体液免疫系统出现。当代补体系统包含近 60 种蛋白质,有三条激活途径(经典途径、替代途径和凝集素途径)和一条共同的终末细胞溶解途径。现代分子生物学和遗传学不仅进一步阐明了补体系统成分的结构,而且还揭示了功能改变的罕见变异和常见多态性,特别是在替代途径的调节剂中,这些变异和多态性通过产生“过度炎症补体表型”而导致人类疾病易感性。为了治疗这些“补体病”,一种针对膜攻击复合物启动子 C5 的单克隆抗体已被批准使用。其他治疗试剂也在研发中。